CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures. Abdel-Haleem AM, Casavant E, Toth B, Teng E, et al. Brain 2025 May 28:awaf200. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Abdel-Haleem AM, Casavant E, Toth B, Teng E, et al. CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures. Brain 2025 May 28:awaf200. doi: 10.1093.
PMID: 40435316